JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yu, Y.
Right arrow Articles by Koss, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, Y.
Right arrow Articles by Koss, M. C.

Vol. 300, Issue 2, 521-525, February 2002

alpha 1A-Adrenoceptors Mediate Sympathetically Evoked Pupillary Dilation in Rats

Yongxin Yu and Michael C. Koss

Department of Cell Biology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma

Evidence suggests that in some species (cats, rabbits, and possibly humans) alpha -adrenoceptors in the iris dilator muscle are "atypical" in that they cannot be readily classified by conventional criteria. This study was undertaken in an attempt to characterize the alpha -adrenoceptor subtype(s) mediating sympathetically elicited mydriasis in rats. Frequency-response pupillary dilator curves were generated by stimulation of the preganglionic cervical sympathetic nerve (1-32 Hz) in pentobarbital-anesthetized rats. Evoked responses were inhibited by systemic administration of nonselective alpha -adrenergic antagonists, phentolamine (0.3-10 mg/kg) and phenoxybenzamine (0.03-1 mg/kg). The selective alpha 1-adrenergic antagonist, prazosin (0.01-1 mg/kg), also was effective, although alpha 2-adrenergic antagonism with rauwolscine (0.1-1 mg/kg) was not. alpha 1A-Adrenoceptor-selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), as well as the alpha 1D-adrenoceptor-selective antagonist 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1-3 mg/kg), were used to determine the subtype(s) involved. Evoked mydriasis was significantly antagonized by both WB-4101 and 5-methylurapidil but not by BMY-7378. These results suggest that, unlike some other species, adrenoceptors in the rat iris dilator mediating neurogenic mydriasis are "typical" and, in addition, can be characterized as being primarily of the alpha 1A-adrenoceptor subtype.


0022-3565/02/3002-0521$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Toxicol SciHome page
P. A. Dabisch, M. S. Horsmon, W. T. Muse, R. J. Mioduszewski, and S. Thomson
Muscarinic Receptor Dysfunction Induced by Exposure to Low Levels of Soman Vapor
Toxicol. Sci., November 1, 2007; 100(1): 281 - 289.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
P. A. Dabisch, F. To, E. K. Kerut, M. S. Horsmon, and R. J. Mioduszewski
Multiple Exposures to Sarin Vapor Result in Parasympathetic Dysfunction in the Eye but not the Heart
Toxicol. Sci., September 1, 2007; 99(1): 354 - 361.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
P. A. Dabisch, D. B. Miller, S. A. Reutter, R. J. Mioduszewski, and S. A. Thomson
Miotic Tolerance to Sarin Vapor Exposure: Role of the Sympathetic and Parasympathetic Nervous Systems
Toxicol. Sci., June 1, 2005; 85(2): 1041 - 1047.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.